Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice
about
Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surfaceEbola virus can be effectively neutralized by antibody produced in natural human infection.Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-beta2.A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus.Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries.Characterization of a type-common human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential.A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein.Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.Construction of human Fab library and isolation of monoclonal Fabs with rabies virus-neutralizing ability.A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo.Construction of human Fab (gamma1/kappa) library and identification of human monoclonal Fab possessing neutralizing potency against Japanese encephalitis virus.Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatmentIntranasal antibody prophylaxis for protection against viral disease.Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice.Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages. Suppression of early cytokine production and implications for incomplete immunityIntranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in miceTreatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature.In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelopeA pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro.Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus.Infant baboons infected with respiratory syncytial virus develop clinical and pathological changes that parallel those of human infantsProphylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.Antibody-based therapies as anti-infective agents.Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.Treatment of respiratory syncytial virus infections in children.Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028).Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen.Leucocyte populations in respiratory syncytial virus-induced bronchiolitis.Sites of replication of bovine respiratory syncytial virus in naturally infected calves as determined by in situ hybridization.
P2860
Q28368071-F2A33E8A-69BC-4227-9211-EA8870F92B66Q30712477-FCA76ABF-DDDB-4C44-A340-D6F48D05C7B3Q30724603-4162644B-98AD-4306-82AF-117DAF2CB176Q30841213-3175F61D-72D1-4A5B-A2C7-09554B84F591Q30933288-B6422183-23DA-4F55-870A-B32F53B27CB3Q31998570-65935BEF-8E51-4B42-9880-CDE7BD3EA673Q32099239-4DCD4B8D-A8B4-45E5-BD84-4B920963830FQ33177627-16FA069F-5E07-483D-9E09-16D1F1E9F7FDQ33180421-CE9563D6-DD89-429A-B0B4-81DC3B8B411DQ33201423-BCFDE3C3-7C2E-4871-8AFA-D62F0F068C4FQ33214241-BE01F75C-AE58-4747-A4DF-B7D96173724CQ33285591-970F89E0-C3FA-45F9-BE80-90F2DD9F99FCQ33288231-7E7F83ED-29C2-461B-A2BA-72E953E04853Q33588916-18EBF1A3-2913-4C74-9FB4-7F5E62367763Q33683058-FBEF7F1D-DB8C-4A18-801A-A9F99B3B75F7Q33782181-19ACB23D-51B5-47B4-BB5D-88CD2BD27E98Q34307704-AD0E3B7A-0171-4EB0-BF13-D5563204ACB4Q34341948-06AF493C-1EDF-4FA0-BE5D-CF2FD733D5ACQ35766589-1734C1E2-9267-4817-865C-BE6A4B835361Q35823116-7C69D07E-9648-4F68-97FA-36D851FE21FCQ35859956-DFA35DDC-67ED-4268-8A16-EC88BA1F2FB3Q35874414-2726AD3B-BD59-4D4F-BC45-714DADACF719Q35886309-42E91ECF-F6A8-4969-AAAD-EFD4F9CB6E40Q36424202-C9AF3165-4246-4781-B680-A064FC5875C6Q36764722-9384ED1B-ACAB-40D9-AB5F-1FAD1AEF1435Q37484236-E86DFA10-BDE2-44FB-9473-742DB27BB163Q39216839-352A62E9-441F-47F9-B4E6-97D12F1AEC59Q39312261-9781A5BC-6111-4417-BF75-47865509DF09Q39789318-9A88DA6B-15FF-43D5-9727-02F3DCD75DB1Q40043685-A63B2B10-C5A4-4FC5-B2AC-E31C184578D8Q40573404-07002408-C457-4409-A79F-0E5F536F6D71Q43724047-27F0C950-0404-4F92-BE0F-F1A81DD1FCC2Q45342736-AD6630D4-A874-4370-BE4B-3D0D8243B7E4Q45737596-D8D83A17-0F71-43A0-B58A-4F9805B6A5D8Q45768052-86321372-50E7-4CD0-9202-1E9E9E415D63
P2860
Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice
description
1994 nî lūn-bûn
@nan
1994 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Recombinant human respiratory ...... the lungs of RSV-infected mice
@en
type
label
Recombinant human respiratory ...... the lungs of RSV-infected mice
@en
prefLabel
Recombinant human respiratory ...... the lungs of RSV-infected mice
@en
P2093
P2860
P356
P1476
Recombinant human respiratory ...... the lungs of RSV-infected mice
@en
P2093
B R Murphy
C F Barbas
D R Burton
R A Williamson
R M Chanock
P2860
P304
P356
10.1073/PNAS.91.4.1386
P407
P577
1994-02-01T00:00:00Z